MENU

Low-Dose mRNA-1273 COVID-19 Vaccine Generates Durable Memory Enhanced by Cross-reactive T Cells

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Research Assistant Professor, Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI)
    BIOGRAPHY

Abstract

Vaccination and infection are two different paths to immunity. Understanding human immune responses to SARS-CoV-2 RNA vaccines is of interest for a panoply of reasons. mRNA vaccines have demonstrated impressive protection from COVID-19; however, durability of immunity has been a major unknown. 

Given evidence that antibodies, CD4+ T cells, and CD8+ T cells can each participate in protective immunity against COVID-19, we measured acute and memory SARS-CoV-2 Spike-specific antibodies, CD4+ T cells and CD8+ T cells in the blood of subjects who received a low dose (25-µg) or standard dose (100-µg) mRNA-1273 COVID-19 vaccine. Vaccine-generated spike-specific memory CD4+ T cells 6 months post-boost were comparable in quantity and quality to COVID-19 cases, including the presence of T follicular helper cells and IFNγ-expressing cells. Spike-specific CD8+ T cells were generated in 88% of subjects, with equivalent memory at 6 months post-boost compared to COVID-19 cases. Lastly, subjects with pre-existing cross-reactive CD4+ T cell memory had increased CD4+ T cell and antibody responses to the vaccine, demonstrating the biological relevance of SARS-CoV-2–cross-reactive CD4+ T cells. In summary, the 25-µg-dose of mRNA-1273 vaccine induces durable and functional T cell and antibody memory at comparable magnitude to natural infection. This work expands our understanding of immune memory to mRNA vaccine in humans, the biological relevance of crossreactive T cells, and possible timing of boosters. 
 

Learning Objectives:

1. Discuss the durability of mRNA vaccine induced immunity.

2. Break down impact of pre-existing crossreactive memory on immune responses to SARS-CoV-2 proteins. 


Show Resources
You May Also Like
MAR 23, 2022 11:00 AM PDT
MAR 23, 2022 11:00 AM PDT
Date: March 23, 2021 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEDT) In this presentation, Dr. Middleton will review the development and deployment of large-scale saliva-based COVID-19 test...
JUN 29, 2022 8:00 AM PDT
JUN 29, 2022 8:00 AM PDT
Date: June 29, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST) As of May 2022, there have been more than 500 million confirmed cases of COVID-19, including numerous variants. Additiona...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
MAY 05, 2022 9:00 AM PDT
C.E. CREDITS
MAY 05, 2022 9:00 AM PDT
Date: May 5, 2022 Time: 9:00am (PDT), 12:00pm (EDT) In a time when there is global urgency around producing and deploying as many COVID-19 vaccines as...
MAY 04, 2022 10:30 AM PDT
C.E. CREDITS
MAY 04, 2022 10:30 AM PDT
The coronavirus SARS-CoV-2 has led to a worldwide pandemic. Beside respiratory symptoms, infected people may develop neurologic dysfunctions such as loss of smell and taste, also seizures, a...
Loading Comments...
Show Resources